Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing facility in China, marking a significant expansion in the country. The new site, known as the Novartis China Haiyan Radioligand Manufacturing Site, is located in Zhejiang province and represents an investment of approximately RMB 600 million (USD 84.6 million). Upon completion, which is slated for the end of 2026, the facility will be the first of its kind in China, dedicated to the production of radioligand therapies.
This state-of-the-art manufacturing site is expected to enhance the production and distribution of innovative radioligand treatments, both within China and internationally. The Haiyan site will join Novartis’s existing major manufacturing facility in Beijing, which was established in 1987, reinforcing the company’s commitment to the Chinese market and its role in advancing healthcare solutions.- Flcube.com
